SAB Member ILC Research
Our Scientific Advisory Board (SAB) members not only help ensure that information developed and shared by LBCA is current, relevant, and accurate, but they also perform their own ILC research.
Recent Studies by Scientific Advisory Board Members
- SAB Founding Chair Steffi Oesterreich, PhD, and SAB member Megan Kruse, MD, are among the co-authors of Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer, a large, collaborative study by three cancer centers that identified differences between invasive lobular carcinoma and incasive ductal carcinoma. The retrospective was published by the Journal of the National Cancer Institute in October.
-
Current SAB Chair Rinath Jeselsohn, MD, and past SAB Chair Otto Metzger, MD, are the co-senior authors of A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. This article was published on August 11 in AACR’s Cancer Research, and the full article can be read here.
- Patrick Derksen, PhD, is a co-author of the Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer appearing in the August 2022 edition of the Annals of Oncology. LBCA-funded researcher Karen Van Balean, MD, is the lead author of this publication.
- Patrick Derksen, PhD, is also a co-author of Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer. The article was published in August 2022 in Modern Pathology.
- Christos Sotirou, MD, PhD, is an author of Timing evolution of lobular breast cancer through phylogenetic analysis. It was first published online by e-BioMedicine in July 22.
-
Rita Mukhtar, MD, recently authored The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study, which appeared in the Annals of Surgical Oncology. Dr. Mukhtar noted, “This study used the National Cancer Database to see whether chemotherapy was associated with a survival benefit in patients with 1-3 positive nodes and Oncotype Recurrence Score ≤25. Interestingly in unadjusted analysis of those under the age of 50, chemotherapy was not associated with improved survival in patients with ILC. The application of trial results such as RxPonder to pre-menopausal women with ILC needs to be studied.”
-
Jason Mouabbi, MD, had his review Invasive lobular carcinoma: an understudied emergent subtype of breast cancer from Breast Cancer Research and Treatment appear in Breast Cancer Research and Treatment.
-
Matthew Sikora, PhD and Rebecca Riggins, PhD were authors of Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models published in AACR Journals.
Congratulations to our SAB members on their latest work
The Lobular Breast Cancer Alliance’s (LBCA) scientific advisors are an internationally renowned group of clinicians and scientists with expertise in ILC research. Below are several members’ most recent research studies. You can find a complete collection of ILC research from our SAB members and others in our ILC Publications Library.
